AZD 3293 (LY 3314814) enters Phase II/III trial for Alzheimers disease- AstraZeneca + Eli Lilly
AstraZeneca and Eli Lilly and Company announced enrolment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer�s disease. AZD 3293, also known as LY 3314814, has been shown in Phase I studies to reduce levels of amyloid-beta in the cerebro-spinal fluid of Alzheimer�s patients and healthy volunteers. The pivotal study will investigate the safety and efficacy of AZD 3293/LY 3314814 compared with placebo in the treatment of early Alzheimer�s disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.